Scarica l'app Stockscreener
317.25
4.71%
-15.67
Precedente Chiudi:
$332.92
Aprire:
$332.74
Volume 24 ore:
332.17K
Relative Volume:
0.47
Capitalizzazione di mercato:
$8.80B
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-34.60
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
-0.73%
1M Prestazione:
+12.97%
6M Prestazione:
+546.79%
1 anno Prestazione:
+266.09%
Intervallo 1D:
$315.42
$333.52
Intervallo di 1 settimana:
$302.00
$335.75
Portata 52W:
$26.70
$335.75
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
317.25 | 9.23B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Wells Fargo | Equal Weight |
| 2025-12-15 | Reiterato | Oppenheimer | Outperform |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress - Yahoo Finance
Can Praxis Precision Medicines Inc. outperform in the next rallyProfit Target & Reliable Price Action Trade Plans - mfd.ru
Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800 - Finviz
Is Praxis Precision Medicines Inc. exposed to currency risks2025 AllTime Highs & Real-Time Chart Pattern Alerts - mfd.ru
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
Praxis Precision Medicines stock hits 52-week high at 327.0 USD - Investing.com Nigeria
Is Praxis Precision Medicines Inc.’s ROIC above industry average2025 Biggest Moves & Fast Moving Stock Trade Plans - mfd.ru
PRAX: Two NDAs set for mid-February aim to address major CNS markets with strong launch plans - TradingView
Arizona State Retirement System Purchases Shares of 5,417 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Will Praxis Precision Medicines Inc. stock attract more institutional investors2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) | PRAX Stock News - GuruFocus
Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity By Investing.com - Investing.com South Africa
Guggenheim raises Praxis Precision Medicines stock price target on essential tremor opportunity - Investing.com Canada
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighHere's Why - MarketBeat
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences - Investing News Network
Praxis Precision Medicines to Report Fourth Quarter and - GlobeNewswire
Praxis Precision Medicines stock hits 52-week high at 327.0 USD By Investing.com - Investing.com South Africa
A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (PRAX) Movement - Stock Traders Daily
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 6-FEB-2026. - marketscreener.com
Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 6-FEB-2026. - marketscreener.com
Is Praxis Precision Medicines (PRAX) Now Pricing In Recent Pipeline Progress And Volatile Share Gains - Sahm
Praxis Precision Medicines (PRAX) Price Target Increased by 26.75% to 597.99 - Nasdaq
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines, Inc. announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Needham Raises Price Target for Praxis Precision Medicine (PRAX) - GuruFocus
Needham & Company LLC Boosts Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $510.00 - MarketBeat
Why Praxis Precision Medicines (PRAX) Is Up 5.1% After Dual NDA Plans And Data Platform Expansion - Sahm
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Wells Fargo Initiates Coverage of Praxis Precision Medicines (PRAX) with Equal-Weight Recommendation - Nasdaq
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders - 01net
Wells Fargo Initiates Coverage on PRAX with Equal-Weight Rating - GuruFocus
Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target - marketscreener.com
Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at Wells Fargo & Company - MarketBeat
A Look At Praxis Precision Medicines (PRAX) Valuation After Breakthrough NDA Plans And Rising Investor Interest - Sahm
Aug Chart Watch: Is Praxis Precision Medicines Inc stock a smart retirement pickAnalyst Upgrade & Safe Capital Growth Tips - baoquankhu1.vn
3,846 Shares in Praxis Precision Medicines, Inc. $PRAX Acquired by Coastal Bridge Advisors LLC - MarketBeat
Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Exploring a 63% Upside in the Biotech Sector - DirectorsTalk Interviews
PRAX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | PRAX Stock News - GuruFocus
H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 - Investing.com Nigeria
Y Intercept Hong Kong Ltd Makes New $1.71 Million Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
Phoenix Financial Ltd. Makes New Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 - Investing.com Canada
Is Praxis Precision Medicines Inc part of any major indexTrade Analysis Report & Daily Market Momentum Tracking - baoquankhu1.vn
Piper Sandler Raises PRAX Price Target to $1,200, Maintains Overweight Rating | PRAX Stock News - GuruFocus
Discipline and Rules-Based Execution in PRAX Response - Stock Traders Daily
A Look At Praxis Precision Medicines (PRAX) Valuation As Late Stage Epilepsy Plans Move Toward FDA Filings - Sahm
Should Praxis Precision Medicines’ (PRAX) New Clinical Strategy Chief Reshape Its Long-Term Epilepsy Investment Story? - Sahm
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $450 - 富途牛牛
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Praxis Precision Medicines Inc Azioni (PRAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):